TheranosticTrials.org

Clinical Trial · NCT05744115

Ga-68-PSMA-11 in Men With Prostate Cancer

Overview

The purpose of this study is to provide access to Ga-68-PSMA-11 PET for evaluation of male veterans with newly diagnosed or biochemically recurrent prostate cancer. All patients will receive conventional imaging (MRI, CT, and/or a molecular imaging bone scan) as well as Ga-68-PSMA-11 PET in order to evaluate the utility of diagnostic testing in patients with positive PSA status, a comparison of results from conventional imaging and PSMA PET imagining will be performed.

Sponsor

Unknown Organization

Phase

Phase 3

Contacts

Timothy J Hoffman, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT05744115

Drug / Compound

PSMA-11

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC

Eligibility

Inclusion

  • Biochemical Recurrence: Patients with rising PSA after definitive therapy with prostatectomy or radiation therapy or other local therapies
  • Patients with newly diagnosed prostate cancer with primary staging classified at high/intermediate risk per NCCN guidelines OR
  • Able to tolerate PET/CT imaging and one or more of the following:

Exclusion

  • Claustrophobia or any other condition that would preclude PET/CT imaging.
  • Any constellation of medical conditions that indicate expectancy of less than one year